Turkiye Klinikleri Journal of Health Sciences

.: REVIEW
Obezite, COVID-19 Pandemisinde Risk Faktörü müdür?
Is Obesity a Risk Factor in COVID-19 Pandemic?
Murat GÜRBÜZa, Leyla TEVFİKOĞLU PEHLİVANa
aTrakya Üniversitesi Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Edirne, TÜRKİYE
Turkiye Klinikleri J Health Sci. 2020;5(2):313-22
doi: 10.5336/healthsci.2020-75675
Article Language: TR
Full Text
ÖZET
 Obezite prevalansının artış göstermeye devam etmesiyle birlikte, bulaşıcı hastalık üzerindeki rolü konusunda farkındalık artmaya başlamıştır. H1N1 influenza A (2009) pandemisi ile obezite ilk kez hastalık şiddeti ve mortalite için risk faktörü olarak tanımlanmıştır. Aynı şekilde bugün obezite, COVID-19 pandemisi için de bağımsız bir risk faktörü olarak değerlendirilmektedir. Aşırı beslenme sonucu gelişen obezite, vücutta sistemik etkileri olan düşük düzeyde kronik inflamasyona neden olmaktadır. Bu durum obez bireylerde kronik metabolik hastalıkları ve enfeksiyonlara karşı duyarlılığı artırmaktadır. Obez bireyler enfeksiyonlara karşı geç ve etkin olmayan antiviral immün yanıtlar sergilemektedir. Ayrıca obez bireylerde tedavide kullanılan ilaç ve aşıların etkinliği azalmakta ve bu durum şiddetli hastalık dönemlerine ve daha az iyileşme oranına neden olmaktadır. Hubei eyaletinin Wuhan kentinde ortaya çıkan pandemik SARS-CoV-2 virüsü de özellikle obezitenin fazla olduğu Kuzey Amerika ve Avrupa ülkeleri başta olmak üzere dünya genelinde yayılmaya devam etmektedir. İnsanlarda ve hayvan modellerinde yapılan çalışmalar, obezitenin alt solunum yollarına viral yayılımı artırabileceğini ve sekonder enfeksiyonlara neden olarak hastalık şiddetini ve mortaliteyi artırabileceğini vurgulamaktadır. Artık çocukluk çağında dahi artış gösteren obezite, gelecek jenerasyon için sağlık riskini artıran önemli bir halk sağlığı sorunu olarak karşımıza çıkmaktadır. Obezitede gün geçtikçe hızlanan bu yükseliş trendinin bulaşıcı hastalıklar üzerine etkisi, ilerleyen yıllarda sağlık harcamalarının artması ile birlikte küresel çapta daha önemli bir sorun olarak karşımıza çıkacaktır.

Anahtar Kelimeler: Obezite; enfeksiyon; immün sistem; COVID-19; SARS-CoV-2
ABSTRACT
 As the prevalence of obesity continues to increase, awareness of its role on infectious disease has begun to increase. With H1N1 influenza A (2009) pandemic, obesity was first defined as a risk factor for disease severity and mortality. Similarly, obesity is considered an independent risk factor for COVID-19 pandemic today. Obesity due to overfeeding causes low levels of chronic inflammation with systemic effects on the body. This situation increases the susceptibility to chronic metabolic diseases and infections in obese individuals. Obese individuals show late and ineffective antiviral immune responses to infections. In addition, the effectiveness of drugs and vaccines used in the treatment of obese individuals decreases and this causes severe disease periods and less recovery rate. The pandemic SARS-CoV-2 virus, which occurs in Wuhan, Hubei province, continues to spread worldwide, especially in North America and European countries where obesity is high. Studies in humans and animal models emphasize that obesity can increase viral spread to the lower respiratory tract and increase disease severity and mortality by causing secondary infections. Obesity, which is now increasing even in childhood, is an important public health problem that increases health risk for the next generation. The effect of this rising trend, which has been accelerating day by day in obesity, will be a more important problem on a global scale with the increase in health expenditures in the following years.

Keywords: Obesity; infection; immun system; COVID-19; SARS-CoV-2
REFERENCES:
  1. San-Cristobal R, Navas-Carretero S, Martínez-González MA, Ordovas JM, Martínez JA. Contribution of macronutrients to obesity: implications for precision nutrition. Nature Reviews Endocrinology. 2020;16:305-20. [Crossref]  [PubMed] 
  2. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American association of clinical endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):642-8. [Crossref]  [PubMed] 
  3. Tobore TO. Towards a comprehensive theory of obesity and a healthy diet: the causal role of oxidative stress in food addiction and obesity. Behav Brain Res. 2020;20;384:112560. [Crossref]  [PubMed] 
  4. WHO: WHO fact sheet on overweight and obesity. 2016. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Access Date: 12 April 2020
  5. Rico-Campà A, Martínez-González MA, Alvarez-Alvarez I, de Deus Mendonça R, de la Fuente-Arrillaga C, Gómez-Donoso C, et al. Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study. BMJ. 2019;365:l1949. [Crossref]  [PubMed]  [PMC] 
  6. Ojiambo RM, Easton C, Casajús JA, Konstabel K, Reilly JJ, Pitsiladis Y, et al. Effect of urbanization on objectively measured physical activity levels, sedentary time, and indices of adiposity in Kenyan adolescents. J Phys Act Health. 2012;9(1):115-23. [Crossref]  [PubMed] 
  7. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;12;377(9765):557-67. [Crossref]  [PubMed] 
  8. Asghar A, Sheikh N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell Immunol. 2017;315:18-26. [Crossref]  [PubMed] 
  9. Rojas-Osornio SA, Cruz-Hernández TR, Drago-Serrano ME, Campos-Rodríguez R. Immunity to influenza: impact of obesity. Obes Res Clin Pract. 2019;13(5):419-29. [Crossref]  [PubMed] 
  10. Honce R, Schultz-Cherry S. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. Front Immunol. 2019;10;10:1071. [Crossref]  [PubMed]  [PMC] 
  11. Martin ET, Archer C, McRoberts J, Kulik J, Thurston T, Lephart P, et al. Epidemiology of severe influenza outcomes among adult patients with obesity in Detroit, Michigan, 2011. Influenza Other Respir Viruses. 2013;7(6):1004-7. [Crossref]  [PubMed]  [PMC] 
  12. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. Obes Rev. 2011;12(8):653-9. [Crossref]  [PubMed] 
  13. Neidich SD, Green WD, Rebeles J, Karlsson EA, Schultz-Cherry S, Noah TL, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes (Lond). 2017;41(9):1324-30. [Crossref]  [PubMed]  [PMC] 
  14. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;1;318(5):E736-E741. [Crossref]  [PubMed] 
  15. Mu-oz-Carrillo JL, Castro García FP, Coronado OG, Moreno García MA, Cordero JFC. Physiology and pathology of innate immune response against pathogens. InTech. 2017:100-34. [Crossref] 
  16. Hall JE. Guyton and Hall Textbook of Medical Physiology. 13th ed. Philadelphia, PA: Elsevier; 2016. p.1168.
  17. Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med. 2013;5(5):661-74. [Crossref]  [PubMed]  [PMC] 
  18. Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. 2016;15;7(1):66-75. [Crossref]  [PubMed]  [PMC] 
  19. Singer K, DelProposto J, Morris DL, Zamarron B, Mergian T, Maley N, et al. Diet-induced obesity promotes myelopoiesis in hematopoietic stem cells. Mol Metab. 2014;10;3(6):664-75. [Crossref]  [PubMed]  [PMC] 
  20. van den Berg SM, Seijkens TTP, Kusters PJH, Beckers L, den Toom M, Smeets E, et al. Diet-induced obesity in mice diminishes hematopoietic stem and progenitor cells in the bone marrow. FASEB J. 2016;30(5):1779-88. [Crossref]  [PubMed] 
  21. Friedrich K, Sommer M, Strobel S, Thrum S, Blüher M, Wagner U, et al. Perturbation of the monocyte compartment in human obesity. Front Immunol. 2019;8;10:1874. [Crossref]  [PubMed]  [PMC] 
  22. Farahi N, Loutsios C, Tregay N, Wright AKA, Berair R, Lok LSC, et al. In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients. J Allergy Clin Immunol. 2018;142(5):1659-62.e8. [Crossref]  [PubMed]  [PMC] 
  23. Adler BJ, Green DE, Pagnotti GM, Chan ME, Rubin CT. High fat diet rapidly suppresses B lymphopoiesis by disrupting the supportive capacity of the bone marrow niche. PLoS One. 2014;4;9(3):e90639. [Crossref]  [PubMed]  [PMC] 
  24. Manicone AM, Gong K, Johnston LK, Giannandrea M. Diet-induced obesity alters myeloid cell populations in naïve and injured lung. Respir Res. 2016;8;17:24. [Crossref]  [PubMed]  [PMC] 
  25. Ramírez-Orozco RE, Franco Robles E, Pérez Vázquez V, Ramírez Emiliano J, Hernández Luna MA, López Briones S, et al. Diet-induced obese mice exhibit altered immune responses to early Salmonella Typhimurium oral infection. J Microbiol. 2018; 56(9):673-82. [Crossref]  [PubMed] 
  26. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-5. [Crossref]  [PubMed]  [PMC] 
  27. Martin-Gayo E, Yu XG. Role of Dendritic cells in natural immune control of HIV-1 infection. Front Immunol. 2019;6;10:1306. [Crossref]  [PubMed]  [PMC] 
  28. Pizzolla A, Oh DY, Luong S, Prickett SR, Henstridge DC, Febbraio MA, et al. High fat diet inhibits dendritic cell and t cell response to allergens but does not impair inhalational respiratory tolerance. PLoS One. 2016;2;11(8): e0160407. [Crossref]  [PubMed]  [PMC] 
  29. O'Shea D, Corrigan M, Dunne MR, Jackson R, Woods C, Gaoatswe G, et al. Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection. Int J Obes (Lond). 2013;37(11):1510-3. [Crossref]  [PubMed] 
  30. Lau Y, Peiris JSM, Law HKM. Role of dendritic cells in SARS coronavirus infection. Hong Kong Med J. 2012;18 Suppl (3):28-30. [PubMed] 
  31. Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell. 2017;1;20(6):771-84.e6. [Crossref]  [PubMed]  [PMC] 
  32. Solt CM, Hill JL, Vanderpool K, Foster MT. Obesity-induced immune dysfunction and immunosuppression: TEM observation of visceral and subcutaneous lymph node microarchitecture and immune cell interactions. Horm Mol Biol Clin Investig. 2019;28;39(2):/j/hmbci.2019.39.issue-2/hmbci-2018-0083/hmbci-2018-0083.xml. [Crossref]  [PubMed] 
  33. Yang H, Youm YH, Vandanmagsar B, Rood J, Kumar KG, Butler AA, et al. Obesity accelerates thymic aging. Blood. 2009;29;114(18):3803-12. [Crossref]  [PubMed]  [PMC] 
  34. Suárez-Cuenca JA, Ruíz-Hernández AS, Mendoza-Casta-eda AA, Domínguez-Pérez GA, Hernández-Patricio A, Vera-Gómez E, et al. Neutrophil-to-lymphocyte ratio and its relation with pro-inflammatory mediators, visceral adiposity and carotid intima-media thickness in population with obesity. Eur J Clin Invest. 2019;49(5):e13085. [Crossref]  [PubMed] 
  35. Rodríguez-Rodríguez E, López-Sobaler AM, Ortega RM, Delgado-Losada ML, López-Parra AM, Aparicio A, et al. Association between neutrophil-to-lymphocyte ratio with abdominal obesity and healthy eating index in a representative older spanish population. Nutrients. 2020;23;12(3):855. [Crossref]  [PubMed]  [PMC] 
  36. Zheng X, Zhang L, Chen J, Gu Y, Xu J, Ouyang Y, et al. Dendritic cells and Th17/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease. Biomed Pharmacother. 2018;108:1141-51. [Crossref]  [PubMed] 
  37. Ye J, Liu H, Zhang G, Li P, Wang Z, Huang S, et al. The treg/th17 imbalance in patients with obstructive sleep apnoea syndrome. Mediators Inflamm. 2012;2012:815308. [Crossref]  [PubMed]  [PMC] 
  38. Paich HA, Sheridan PA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens MG, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza a virus. Obesity (Silver Spring). 2013;21(11):2377-86. [Crossref]  [PubMed]  [PMC] 
  39. Akimova T, Zhang T, Beier UH, Jiao J, Diamond JM, Christie JD, et al. Obesity-driven IL-18 inhibits the suppressive function of FOXP3+ T-regulatory (Treg) cells. J Immunol. 2018;200(1 Suppl):166.52.
  40. Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol. 2010;15;184(6):3127-33. [Crossref]  [PubMed] 
  41. Farnsworth CW, Schott EM, Benvie A, Kates SL, Schwarz EM, Gill SR, et al. Exacerbated Staphylococcus aureus foot infections in obese/diabetic mice are associated with impaired germinal center reactions, Ig class switching, and humoral ımmunity. J Immunol. 2018;15;201(2):560-72. [Crossref]  [PubMed]  [PMC] 
  42. Milner JJ, Sheridan PA, Karlsson EA, Schultz-Cherry S, Shi Q, Beck MA, et al. Diet-induced obese mice exhibit altered heterologous immunity during a secondary 2009 pandemic H1N1 infection. J Immunol. 2013;1;191(5): 2474-85. [Crossref]  [PubMed]  [PMC] 
  43. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;7;323(11):1061-69. [Crossref]  [PubMed]  [PMC] 
  44. Zeng Q, Li YZ, Huang G, Wu W, Dong SY, Xu Y, et al. Mortality of COVID-19 is associated with cellular immune function compared to immune function in Chinese han population. MedRxiv. [Crossref] 
  45. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727-32. [Crossref]  [PubMed]  [PMC] 
  46. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499-522. [Crossref]  [PubMed]  [PMC] 
  47. Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Negl Trop Dis. 2020;8;14(5):e0008280. [Crossref]  [PubMed]  [PMC] 
  48. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA. 2020;24. [Crossref]  [PubMed] 
  49. Yu S, Xing L, Du Z, Tian Y, Jing L, Yan H, et al. Prevalence of obesity and associated risk factors and cardiometabolic comorbidities in rural northeast China. BioMed Res Int. 2019;25;2019:6509083. [Crossref]  [PubMed]  [PMC] 
  50. Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1730-5. [Crossref]  [PubMed]  [PMC] 
  51. Petermann-Rocha F, Yang S, Gray SR, Pell JP, Celis-Morales C, Ho FK, et al. Sarcopenic obesity and its association with respiratory disease incidence and mortality. Clin Nutr. 2020;12;S0261-5614(20):30109-6. [PubMed] 
  52. Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016;57(12):2099-114. [Crossref]  [PubMed]  [PMC] 
  53. León-Pedroza JI, González-Tapia LA, del Olmo-Gil E, Castellanos-Rodríguez D, Escobedo G, González-Chávez A, et al. [Low-grade systemic inflammation and the development of metabolic diseases: from the molecular evidence to the clinical practice]. Cir Cir. 2015;83(6):543-51. [Crossref]  [PubMed] 
  54. Sudhakar M, Silambanan S, Chandran AS, Prabhakaran AA, Ramakrishnan R. C-Reactive Protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor. Front Immunol. 2018;29;9:1167. [Crossref]  [PubMed]  [PMC] 
  55. Li M, Xu C, Shi J, Ding J, Wan X, Chen D, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Gut. 2018;67(12):2169-80. [Crossref]  [PubMed]  [PMC] 
  56. Fernø J, Strand K, Mellgren G, Stiglund N, Björkström NK. Natural killer cells as sensors of adipose tissue stress. Trends Endocrinol Metab. 2020;31(1):3-12. [Crossref]  [PubMed] 
  57. Carbone S, Del Buono MG, Ozemek C, Lavie CJ. Obesity, risk of diabetes and role of physical activity, exercise training and cardiorespiratory fitness. Prog Cardiovasc Dis. 2019;62(4):327-33. [Crossref]  [PubMed] 
  58. Burhans MS, Hagman DK, Kuzma JN, Schmidt KA, Kratz M. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol. 2018;13;9(1):1-58. [Crossref]  [PubMed] 
  59. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med. 2006;23(6):623-8. [Crossref]  [PubMed] 
  60. Morra ME, Thanh LV, Kamel MG, Ghazy AA, Altibi AMA, Dat LM, et al. Clinical outcomes of current medical approaches for middle east respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28(3):e1977. [Crossref]  [PubMed]  [PMC] 
  61. Hill MA, Mantzoros C, Sowers JR: Commentary: COVID-19 in patients with diabetes. Metabolism. 2020;107:154217. [Crossref]  [PubMed]  [PMC] 
  62. Kohio HP, Adamson AL: Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013;444(1-2):301-9. [Crossref]  [PubMed] 
  63. Alim MA, Sikder S, Sathkumara H, Kupz A, Rush CM, Govan BL, et al. Dysregulation of key cytokines may contribute to increased susceptibility of diabetic mice to Mycobacterium bovis BCG infection. Tuberculosis (Edinb). 2019;115:113-20. [Crossref]  [PubMed] 
  64. Kim JH, Park K, Lee SB, Kang S, Park JS, Ahn CW, et al. Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. J Diabetes Investig. 2019;10(5):1223-28. [Crossref]  [PubMed]  [PMC] 
  65. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33(5):386-93. [Crossref]  [PubMed] 
  66. Hall JE. Renal dysfunction, rather than nonrenal vascular dysfunction, mediates salt-induced hypertension. Circulation. 2016;1;133(9):894-906. [Crossref]  [PubMed]  [PMC] 
  67. Shen C, Zhou Z, Lai S, Tao X, Zhao D, Dong W, et al. Urban-rural-specific trend in prevalence of general and central obesity, and association with hypertension in Chinese adults, aged 18-65 years. BMC Public Health. 2019;30;19(1):661. [Crossref]  [PubMed]  [PMC] 
  68. Christiansen SC, Schatz M, Yang SJ, Ngor E, Chen W, Zuraw BL, et al. Hypertension and asthma: a comorbid relationship. J Allergy Clin Immunol Pract. 2016;4(1):76-81. [Crossref]  [PubMed] 
  69. Zhu Z, Wang X, Li X, Lin Y, Shen S, Liu C-L, et al. Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis. Respir Res. 2019;2;20(1):64. [Crossref]  [PubMed]  [PMC] 
  70. Syammakh M, Anthonius F. Hypertensive crisis induced acute pulmonary edema in emergency care unit Sumbawa hospital: a case report. Int J Res Med Sci. 2018;6;(12):4122-7. [Crossref] 
  71. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring). 2020;28(6):1005. [Crossref]  [PubMed] 
  72. Greffin S, André MB, Matos JPS, Kang HC, Jorge AJL, Rosa MLG, et al. [Chronic kidney disease and metabolic syndrome as risk factors for cardiovascular disease in a primary care program]. J Bras Nefrol. 2017;39(3):246-52. [Crossref]  [PubMed] 
  73. Hess PL, Al-Khalidi HR, Friedman DJ, Mulder H, Kucharska-Newton A, Rosamond WR, et al. The metabolic syndrome and risk of sudden cardiac death: the atherosclerosis risk in communities study. J Am Heart Assoc. 2017;23;6(8):e006103. [Crossref]  [PubMed] 
  74. Yeh TL, Chen HH, Tsai SY, Lin CY, Liu SJ, Chien KL, et al. The relationship between metabolically healthy obesity and the risk of cardiovascular disease: a systematic review and meta-analysis. J Clin Med. 2019;15;8(8):1228. [Crossref]  [PubMed]  [PMC] 
  75. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu-iga FA, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;31;17(1):122. [Crossref]  [PubMed]  [PMC] 
  76. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1;1(3):274-81. [Crossref]  [PubMed]  [PMC] 
  77. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50. [Crossref]  [PubMed]  [PMC] 
  78. Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, et al. Association of cardiovascular disease with respiratory disease. J Am Coll Cardiol. 2019;7;73(17):2166-77. [Crossref]  [PubMed] 
  79. Frank RC, Min J, Abdelghany M, Paniagua S, Bhattacharya R, Bhambhani V, et al. Obesity is associated with pulmonary hypertension and modifies outcomes. J Am Heart Assoc. 2020;3;9(5):e014195. [Crossref]  [PubMed]  [PMC] 
  80. Lecube A, Sampol G, Mu-oz X, Hernández C, Mesa J, Simó R, et al. Type 2 diabetes impairs pulmonary function in morbidly obese women: a case-control study. Diabetologia. 2010;53(6):1210-6. [Crossref]  [PubMed] 
  81. Rossi A, Fantin F, Di Francesco V, Guariento S, Giuliano K, Fontana G, et al. Body composition and pulmonary function in the elderly: a 7-year longitudinal study. Int J Obes. 2008;32(9):1423-30. [Crossref]  [PubMed] 
  82. Zammit C, Liddicoat H, Moonsie I, Makker H. Obesity and respiratory diseases. Int J Gen Med. 2010;20;3:335-43. [PubMed] 
  83. Azizpour Y, Delpisheh A, Montazeri Z, Sayehmiri K, Darabi B. Effect of childhood BMI on asthma: a systematic review and meta-analysis of case-control studies. BMC Pediatr. 2018;26;18(1):143. [Crossref]  [PubMed]  [PMC] 
  84. Grewal G, Joshi GP. Obesity and obstructive sleep apnea in the ambulatory patient. Anesthesiol Clin. 2019;37(2):215-24. [Crossref]  [PubMed] 
  85. Fuller-Thomson E, Howden KEN, Fuller-Thomson LR, Agbeyaka S. A Strong graded relationship between level of obesity and COPD: findings from a national population-based study of lifelong nonsmokers. J Obes. 2018:6149263. [Crossref]  [PubMed]  [PMC] 
  86. Endo Y, Asou HK, Matsugae N, Hirahara K, Shinoda K, Tumes DJ, et al. Obesity drives th17 cell differentiation by inducing the lipid metabolic kinase, ACC1. Cell Rep. 2015;11;12(6):1042-55. [Crossref]  [PubMed] 
  87. Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019;19;23(1):258. [Crossref]  [PubMed]  [PMC] 
  88. Karlsson EA, Meliopoulos VA, van de Velde NC, van de Velde LA, Mann B, Gao G, et al. A perfect storm: increased colonization and failure of vaccination leads to severe secondary bacterial infection in influenza virus-infected obese mice. mBio. 2017;19;8(5): e00889-17. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com